MA33109B1 - Traitement d'un cancer du pancreas - Google Patents

Traitement d'un cancer du pancreas

Info

Publication number
MA33109B1
MA33109B1 MA34154A MA34154A MA33109B1 MA 33109 B1 MA33109 B1 MA 33109B1 MA 34154 A MA34154 A MA 34154A MA 34154 A MA34154 A MA 34154A MA 33109 B1 MA33109 B1 MA 33109B1
Authority
MA
Morocco
Prior art keywords
iodophenylamino
fluoro
salt
treatment
pharmaceutical
Prior art date
Application number
MA34154A
Other languages
Arabic (ar)
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33109(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MA33109B1 publication Critical patent/MA33109B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LE DOMAINE DE L'ONCOLOGIE ET L'UTILISATION DU (S)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHÉNYLAMINO)-6-MÉTHOXYPHÉNYL)-1-(2,3-DIHYDROXYPROPYL) CYCLOPROPANE-1-SULFONAMIDE OU D'UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI OU DU N-(4-(2-FLUORO-4-IODOPHÉNYLAMINO)-1,5-DIMÉTHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL) CYCLOPROPANESULFONAMIDE OU D'UN POLYMORPHE DE CELUI-CI OU D'UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI OU DE COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT, POUR LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ AU TRAITEMENT DU CANCER DU PANCRÉAS. EN OUTRE, LA PRÉSENTE INVENTION PORTE SUR DES PROCÉDÉS D'ADMINISTRATION D'UN COMPOSÉ DÉCRIT PAR LES PRÉSENTES, À UN INDIVIDU QUI EN A BESOIN, LESQUELS PROCÉDÉS CONSISTENT EN L'ADMINISTRATION DE (S)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHÉNYLAMINO)-6-MÉTHOXYPHÉNYL)-1-(2,3-DIHYDROXYPROPYL) CYCLOPROPANE-1-SULFONAMIDE OU D'UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI OU DE N-(4-(2-FLUORO-4-IODOPHÉNYLAMINO)-1,5-DIMÉTHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL) CYCLOPROPANESULFONAMIDE OU D'UN POLYMORPHE DE CELUI-CI OU D'UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI, OU DE COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT.
MA34154A 2009-03-11 2010-03-11 Traitement d'un cancer du pancreas MA33109B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15939709P 2009-03-11 2009-03-11
PCT/US2010/027021 WO2010105082A1 (fr) 2009-03-11 2010-03-11 Traitement d'un cancer du pancréas

Publications (1)

Publication Number Publication Date
MA33109B1 true MA33109B1 (fr) 2012-03-01

Family

ID=42129806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34154A MA33109B1 (fr) 2009-03-11 2010-03-11 Traitement d'un cancer du pancreas

Country Status (20)

Country Link
US (1) US20120053211A1 (fr)
EP (1) EP2405907A1 (fr)
JP (1) JP2012520319A (fr)
KR (1) KR20110128916A (fr)
CN (1) CN102438609A (fr)
AU (1) AU2010224108A1 (fr)
BR (1) BRPI1009435A2 (fr)
CA (1) CA2754891A1 (fr)
CL (1) CL2011002234A1 (fr)
CR (1) CR20110478A (fr)
EA (1) EA201101305A1 (fr)
IL (1) IL215037A0 (fr)
MA (1) MA33109B1 (fr)
MX (1) MX2011009494A (fr)
SG (1) SG174271A1 (fr)
SV (1) SV2011004017A (fr)
TN (1) TN2011000456A1 (fr)
TW (1) TW201100081A (fr)
UY (1) UY32486A (fr)
WO (1) WO2010105082A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010317167B2 (en) 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
ES2957388T3 (es) 2016-07-15 2024-01-18 H2 Water Tech Ltd Composición para producir agua rica en hidrógeno
KR101980809B1 (ko) * 2017-09-29 2019-05-21 대한민국 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8005A (en) * 1851-04-01 He ne y bo o t
US9022A (en) * 1852-06-15 Organ
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
JP5269762B2 (ja) * 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
EA032294B1 (ru) * 2007-07-30 2019-05-31 Арди Байосайенсиз, Инк. Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
CL2011002234A1 (es) 2012-01-27
CA2754891A1 (fr) 2010-09-16
KR20110128916A (ko) 2011-11-30
BRPI1009435A2 (pt) 2016-03-01
US20120053211A1 (en) 2012-03-01
CN102438609A (zh) 2012-05-02
EP2405907A1 (fr) 2012-01-18
IL215037A0 (en) 2011-11-30
SG174271A1 (en) 2011-10-28
WO2010105082A1 (fr) 2010-09-16
CR20110478A (es) 2011-10-24
JP2012520319A (ja) 2012-09-06
MX2011009494A (es) 2011-10-11
UY32486A (es) 2010-10-29
SV2011004017A (es) 2012-01-06
EA201101305A1 (ru) 2012-04-30
TW201100081A (en) 2011-01-01
TN2011000456A1 (en) 2013-03-27
AU2010224108A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
MA33109B1 (fr) Traitement d'un cancer du pancreas
Wahaib et al. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
BRPI0412054A (pt) preparação farmacêutica transdérmica
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
Budde et al. A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
MA56226B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MA33491B1 (fr) Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
MA39784B1 (fr) Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA35716B1 (fr) Formulations pharmaceutiques
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
FR2967578B1 (fr) Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ZA202407225B (en) Salt and crystal form of dipeptidyl peptidase inhibitor compound
Orjuela-Sánchez et al. Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
JOP20210079A1 (ar) التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2
US20240299382A1 (en) Compounds and methods for degrading rcor1, lsd1, hdac1 and hdac2 in the corest